Vacuolar ATPase 'a2' isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer

Oncotarget

Volumn 6, Issue 6, 2015, Pages 3797-3810

  Kulshrestha, Arpita ^a   Katara, Gajendra K ^a   Ibrahim, Safaa ^a,b   Pamarthy, Sahithi ^a   Jaiswal, Mukesh K ^a   Sachs, Alice Gilman ^a   Beaman, Kenneth D ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

A2 isoform; Cortactin; Invasion; MMP; Ovarian cancer; Vacuolar ATPase

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE A2; CORTACTIN; F ACTIN; GELATINASE A; GELATINASE B; P CADHERIN; UNCLASSIFIED DRUG; ISOENZYME; MATRIX METALLOPROTEINASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ARTICLE; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOSOME; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CONFOCAL MICROSCOPY; ENZYMOLOGY; FLOW CYTOMETRY; GENETICS; METABOLISM; OVARY TUMOR; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; ISOENZYMES; MATRIX METALLOPROTEINASES; MICROSCOPY, CONFOCAL; OVARIAN NEOPLASMS; TUMOR MICROENVIRONMENT; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 84924260805     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2902     Document Type: Article

References (53)

1. Morita T, Nagaki T, Fukuda I, Okumura K. Clastogenicity of low pH to various cultured mammalian cells. Mutation Research. 1992; 268:297-305.
2. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ. Acidic pH enhances the invasive behavior of human melanoma cells. Clinical & Experimental Metastasis. 1996; 14:176-186.
3. Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Research. 2007; 67:10627-10630.
4. Nishi T, Forgac M. The vacuolar (H+)-ATPases-nature's most versatile proton pumps. Nature Reviews Molecular Cell Biology. 2002; 3:94-103.
5. Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nature Reviews Molecular Cell Biology. 2007; 8:917-929.
6. Marshansky V, Rubinstein JL, Gruber G. Eukaryotic V-ATPase: novel structural findings and functional insights. Biochimica et Biophysica Acta (BBA). 2014; 1837:857-879.
7. Toyomura T, Oka T, Yamaguchi C, Wada Y, Futai M. Three subunit a isoforms of mouse vacuolar H(+)-ATPase. Preferential expression of the a3 isoform during osteoclast differentiation. The Journal of Biological Chemistry. 2000; 275:8760-8765.
8. Oka T, Murata Y, Namba M, et al. a4, a unique kidney-specific isoform of mouse vacuolar H+-ATPase subunit a. The Journal of Biological Chemistry. 2001; 276:40050-40054.
9. Sennoune SR, Bakunts K, Martinez GM, et al. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. American Journal of Physiology Cell Physiology. 2004; 286:C1443-1452.
10. Lu X, Qin W, Li J, et al. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Research. 2005; 65:6843-6849.
11. De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncology. 2005; 1:779-786.
12. Ohta T, Numata M, Yagishita H, et al. Expression of 16 kDa proteolipid of vacuolar-type H(+)-ATPase in human pancreatic cancer. British Journal of Cancer. 1996; 73:1511-1517.
13. Holliday LS. Vacuolar H+-ATPase: An Essential Multitasking Enzyme in Physiology and Pathophysiology. New Journal of Science. 2014; 2014: Article ID 675430.
14. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Rey JM, Garcia-Garcia A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treatment Reviews. 2009; 35:707-713.
15. Xiao YT, Xiang LX, Shao JZ. Vacuolar H(+)-ATPase. The International Journal of Biochemistry & Cell Biology. 2008; 40:2002-2006.
16. Finbow ME, Harrison MA. The vacuolar H+-ATPase: a universal proton pump of eukaryotes. Biochemical Journal. 1997; 324:697-712.
17. Hinton A, Sennoune SR, Bond S, et al. Function of a subunit isoforms of the V-ATPase in pH homeostasis and in vitro invasion of MDA-MB231 human breast cancer cells. The Journal of Biological Chemistry. 2009; 284:16400-16408.
18. Morel N, Dedieu JC, Philippe JM. Specific sorting of the a1 isoform of the V-H+ATPase a subunit to nerve terminals where it associates with both synaptic vesicles and the presynaptic plasma membrane. Journal of Cell Science. 2003; 116:4751-4762.
19. Hurtado-Lorenzo A, Skinner M, El Annan J, et al. V-ATPase interacts with ARNO and Arf6 in early endosomes and regulates the protein degradative pathway. Nature Cell Biology. 2006; 8:124-136.
20. Ota K, Jaiswal MK, Ramu S, et al. Expression of a2 vacuolar ATPase in spermatozoa is associated with semen quality and chemokine-cytokine profiles in infertile men. PLoS One. 2013; 8:e70470.
21. Toyomura T, Murata Y, Yamamoto A, et al. From lysosomes to the plasma membrane: localization of vacuolar-type H+-ATPase with the a3 isoform during osteoclast differentiation. The Journal of Biological Chemistry. 2003; 278:22023-22030.
22. Hendrix A, Sormunen R, Westbroek W, et al. Vacuolar H+ ATPase expression and activity is required for Rab27B-dependent invasive growth and metastasis of breast cancer. International Journal of Cancer. 2013; 133:843-854.
23. Nishisho T, Hata K, Nakanishi M, et al. The a3 isoform vacuolar type H(+)-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Molecular Cancer Research. 2011; 9:845-855.
24. Kwong C, Gilman-Sachs A, Beaman K. Tumor-associated a2 vacuolar ATPase acts as a key mediator of cancer-related inflammation by inducing pro-tumorigenic properties in monocytes. The Journal of Immunology. 2011; 186:1781-1789.
25. Katara GK, Jaiswal MK, Kulshrestha A, Kolli B, Gilman-Sachs A, Beaman KD. Tumor-associated vacuolar ATPase subunit promotes tumorigenic characteristics in macrophages. Oncogene. 2014; 33:5649-5654.
26. Stewart BW, Kleihues P. World Cancer Report. Lyon: IARC Press; 2003.
27. Nguyen L, Cardenas-Goicoechea SJ, Gordon P, et al. Biomarkers for early detection of ovarian cancer. Womens Health (Lond Engl). 2013; 9:171-85; quiz 86-87.
28. Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nature Reviews Cancer. 2009; 9:415-428.
29. Beaman K, Angkachatchai V, Gilman-Sachs A. TJ6: the pregnancy-associated cytokine. American Journal of Reproductive Immunology. 1996; 35:338-341.
30. Ntrivalas E, Gilman-Sachs A, Kwak-Kim J, Beaman K. The N-terminus domain of the a2 isoform of vacuolar ATPase can regulate interleukin-1beta production from mononuclear cells in co-culture with JEG-3 choriocarcinoma cells. American Journal of Reproductive Immunology. 2007; 57:201-209.
31. Roth P, Aulwurm S, Gekel I, Beier D, Sperry RG, Mittelbronn M, Meyermann R, Beaman KD, Weller M, Wischhusen J. Regeneration and tolerance factor: a novel mediator of glioblastoma-associated immunosuppression. Cancer Research. 2006; 66:3852-3858.
32. Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochimica et Biophysica Acta (BBA). 2007; 1773:642-652.
33. Weaver AM. Invadopodia: specialized cell structures for cancer invasion. Clinical & Experimental Metastasis. 2006; 23:97-105.
34. Iessi E, Marino ML, Lozupone F, Fais S, De Milito A. Tumor acidity and malignancy: novel aspects in the design of anti-tumor therapy. Cancer Therapy. 2008; 6:55-66.
35. Chung C, Mader CC, Schmitz JC, et al. The vacuolar-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer. Laboratory Investigation. 2011; 91:732-743.
36. Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ. Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. American Journal of Physiology. 1993; 265:C1015-1029.
37. Lu X, Qin W. Vacuolar H(+)-ATPase in Cancer Cells: Structure and Function. Atlas of Genetics and Cytogenetics in Oncology and Haematology. September 2011.
38. Barar J, Omidi Y. Dysregulated pH in Tumor Microenvi-ronment Checkmates Cancer Therapy. Bioimpacts. 2013; 3:149-162.
39. Xu J, Xie R, Liu X, et al. Expression and functional role of vacuolar H(+)-ATPase in human hepatocellular carcinoma. Carcinogenesis. 2012; 33:2432-2440.
40. Perez-Sayans M, Garcia-Garcia A, Reboiras-Lopez MD, Gandara-Vila P. Role of V-ATPases in solid tumors: importance of the subunit C (Review). International Journal of Oncology. 2009; 34:1513-1520.
41. Graham RM, Thompson JW, Webster KA. Inhibition of the vacuolar ATPase induces Bnip3-dependent death of cancer cells and a reduction in tumor burden and metastasis. Oncotarget. 2014; 5:1162-1173.
42. Ntrivalas E, Derks R, Gilman-Sachs A, Kwak-Kim J, Levine R, Beaman K. Novel role for the N-terminus domain of the a2 isoform of vacuolar ATPase in interleukin-1beta production. Human Immunology. 2007; 68:469-477.
43. Sennoune SR, Luo D, Martinez-Zaguilan R. Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell Biochemistry and Biophysics. 2004; 40:185-206.
44. Derks R, Beaman K. Regeneration and tolerance factor modulates the effect of adenosine triphosphate-induced interleukin 1 beta secretion in human macrophages. Human Immunology. 2004; 65:676-682.
45. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nature Reviews Immunology. 2009; 9:581-593.
46. MacGrath SM, Koleske AJ. Cortactin in cell migration and cancer at a glance. Journal of Cell Science. 2012; 125:1621-1626.
47. Hurtado-Lorenzo A, Skinner M, El Annan J, Futai M, Sun-Wada GH, Bourgoin S, et al. V-ATPase interacts with ARNO and Arf6 in early endosomes and regulates the protein degradative pathway. Nature Cell Biology. 2006; 8:124-136.
48. Marshansky V, Futai M. The V-type H+-ATPase in vesicular trafficking: targeting, regulation and function. Current Opinion in Cell Biology. 2008; 20:415-426.
49. Kobia F, Duchi S, Deflorian G, Vaccari T. Pharmacologic inhibition of vacuolar H+ ATPase reduces physiologic and oncogenic Notch signaling. Molecular Oncology. 2014; 8:207-220.
50. Rousselle A, Sihn G, Rotteveel M, Bader M. (Pro)renin receptor and V-ATPase: from Drosophila to humans. Clinical Science. 2014; 126:529-536.
51. Fogarty FM, O'Keeffe J, Zhadanov A, Papkovsky D, Ayllon V, O'Connor R. HRG-1 enhances cancer cell invasive potential and couples glucose metabolism to cytosolic/extracellular pH gradient regulation by the vacuolar-H ATPase. Oncogene. Oct 21; 2013.
52. Boomer JS, Lee GW, Givens TS, Gilman-Sachs A, Beaman KD. Regeneration and tolerance factor's potential role in T-cell activation and apoptosis. Hum Immunol. 2000; 61:959-971.
53. Jaiswal MK, Katara GK, Mallers T, Chaouat G, Gilman-Sachs A, Beaman KD. Vacuolar-ATPase isoform a2 regulates macrophages and cytokine profile necessary for normal spermatogenesis in testis. J Leukoc Biol. 2014; 96:337-347.